Systematic review / meta-analysis / 2024
Once-weekly semaglutide 2.4 mg produced significant, sustained weight loss and improved cardiometabolic markers in non-diabetic overweight or obese adults.
A systematic review and meta-analysis of six randomized controlled trials evaluated subcutaneous semaglutide 2.4 mg once weekly versus placebo in 3,962 overweight or obese adults without diabetes. Semaglutide led to significant reductions in body weight percentage (MD: -11.80% [95% CI -12.93, -10.68]; P < 0.00001), absolute body weight (MD: -12.2 kg [95% CI -13.3, -11.1]; P < 0.00001), BMI (MD: -4.5 kg/m2 [95% CI -4.9, -4.1]; P < 0.00001), and waist circumference (MD: -9.4 cm [95% CI -10.1, -8.8]; P < 0.00001). It also significantly improved blood pressure, blood glucose, C-reactive protein, and lipid profiles. Gastrointestinal adverse reactions were the most common adverse effect (RR: 1.49 [95% CI 1.38, 1.60]; P < 0.00001) and were generally mild to moderate and temporary.
- Study type
- Systematic review and meta-analysis of RCTs
- Who was studied
- 3,962 overweight or obese adults without diabetes
- What was measured
- Body weight, BMI, waist circumference, cardiometabolic markers, and adverse effects
THE PAPER
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
Qin W, Yang J, Deng C, Ruan Q, Duan K. Diabetes Obes Metab, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.